Stopping breastfeeding (any) at 3‐4 months · healthy breastfeeding women with healthy term babies
Summary of findings table ‐ Breastfeeding support only probably leads to lower stopping breastfeeding (any) at 3‐4 months compared with usual care (moderate certainty).
1 finding from 1 review
Stopping breastfeeding (any) at 9 months ‐ not reported · healthy breastfeeding women with healthy term babies
Summary of findings table ‐ Breastfeeding support only may leads to lower stopping breastfeeding at 9 months compared with usual care (low certainty).
1 finding from 1 review
Interventions (corticosteroids included in all regimens)a · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
aprepitant + ondansetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy
1 finding from 1 review
fosaprepitant + ondansetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy
1 finding from 1 review
casopitant + ondansetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy
1 finding from 1 review
netupitant + palonosetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy
1 finding from 1 review
aprepitant + ramosetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy
1 finding from 1 review
fosaprepitant + palonosetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy
1 finding from 1 review
fosnetupitant + palonosetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy
1 finding from 1 review
fosaprepitant + granisetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy
1 finding from 1 review
aprepitant + palonosetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy
1 finding from 1 review
rolapitant + granisetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy
1 finding from 1 review
Interventions (corticosteroids included in all regimens)a · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
rolapitant + granisetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy
1 finding from 1 review
FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Quality of life: Quality of Well Being score change from baseline · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in BMI · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to next exacerbation · adults and children with cystic fibrosis
1 finding from 1 review
Adverse events · adults and children with cystic fibrosis
1 finding from 1 review